Please assess the completion status of the following clinical trial:

Trial Title: BOTOX® in the Treatment of Crow's Feet Lines in China

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~-Moderate to severe Crow's Feet Lines.~Exclusion Criteria:~* Current or previous treatment with botulinum toxin of any serotype for any condition within the last year~* Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis~* Facial laser or light treatment, microdermabrasion or chemical peels within 3 months~* Radio frequency laser treatments, phototherapy, blepharoplasty, brow-lift or related procedure, permanent make-up, oral retinoid therapy or treatment with non-permanent soft tissue fillers within 1 year~* Any medium-depth or deep facial peels within 5 years~* Periorbital surgery, face-lift, mid facial or periorbital treatment with permanent soft tissue fillers, synthetic implants or autologous fat transplant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- botulinum toxin type A (Type: EXPERIMENTAL): 24U botulinum toxin Type A (BOTOX®) total dose injected into bilateral Crow's Feet Line areas on Day 1.
- placebo (Type: PLACEBO_COMPARATOR): Placebo (Normal Saline) injected into bilateral Crow's Feet Line areas on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).